UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Amikacin Liposome Inhalation Suspension for Treatment-Refractory Lung Disease Caused by Mycobacterium avium Complex (CONVERT). A Prospective, Open-Label, Randomized Study

American journal of respiratory and critical care medicine, 2018-12, Vol.198 (12), p.1559-1569

2018

Volltextzugriff (PDF)

Diffusing capacity and forced vital capacity in 5,003 asbestos-exposed workers: Relationships to interstitial fibrosis (ILO profusion score) and pleural thickening

American journal of industrial medicine, 2013-12, Vol.56 (12), p.1383-1393

2013

Volltextzugriff (PDF)

Fluticasone Propionate Orally Disintegrating Tablet (APT-1011) for Eosinophilic Esophagitis: Randomized Controlled Trial

Clinical gastroenterology and hepatology, 2022-11, Vol.20 (11), p.2485-2494.e15

2022

Volltextzugriff (PDF)

965 FLUTICASONE PROPIONATE ORAL DISINTEGRATING TABLET, APT-1011, LEADS TO A GREATER COMPLETE SYMPTOMATIC RESPONSE RATE COMPARED TO PLACEBO IN SUBJECTS WITH EOSINOPHILIC ESOPHAGITIS (EOE)

Gastroenterology (New York, N.Y. 1943), 2024-05, Vol.166 (5), p.S-230-S-231

2024

Volltextzugriff (PDF)

964 FLUTICASONE PROPRIONATE ORAL DISINTEGRATING TABLET, APT-1011, IMPROVES FIBROSTENOTIC FEATURES OF STRICTURES AND GRADE 2/3 RINGS IN SUBJECTS WITH EOSINOPHILIC ESOPHAGITIS (EOE)

Gastroenterology (New York, N.Y. 1943), 2024-05, Vol.166 (5), p.S-230-S-230

2024

Volltextzugriff (PDF)

S465 Development and Content Validity of the PROSE Daily Diary to Measure Dysphagia Episodes in Adults and Adolescents With Eosinophilic Esophagitis

The American journal of gastroenterology, 2021-10, Vol.116 (1), p.S205-S206

2021

Volltextzugriff (PDF)

540 FLUTICASONE PROPIONATE ORALLY DISINTEGRATING TABLET (APT-1011) IMPROVES HISTOLOGIC, ENDOSCOPIC AND SYMPTOMATIC RESPONSES IN EOSINOPHILIC ESOPHAGITIS PATIENTS WITH FIBRO-STENOTIC FEATURES: RESULTS FROM A PHASE 2B TRIAL

Gastroenterology (New York, N.Y. 1943), 2021-05, Vol.160 (6), p.S-111-S-112

2021

Volltextzugriff (PDF)

Fr172 LOW RATES OF GLUCOCORTICOID-RELATED ADVERSE EFFECTS WITH LONG-TERM TREATMENT OF EOSINOPHILIC ESOPHAGITIS WITH FLUTICASONE PROPIONATE ORALLY DISINTEGRATING TABLET (APT-1011): RESULTS FROM 52 WEEKS OF EXPOSURE IN A PHASE 2B TRIAL

Gastroenterology (New York, N.Y. 1943), 2021-05, Vol.160 (6), p.S-248-S-249

2021

Volltextzugriff (PDF)

S0345 Safety and Efficacy of Long-Term Treatment of EoE With Fluticasone Propionate Orally Disintegrating Tablet (APT-1011): Results From 40 Weeks Treatment in a Phase 2b Randomized Double-Blind Placebo-Controlled Trial

The American journal of gastroenterology, 2020-10, Vol.115 (1), p.S169-S170

2020

Volltextzugriff (PDF)

Mo1184 AN EPISODE-BASED PATIENT-REPORTED OUTCOME MEASURE OF DYSPHAGIA EXPERIENCE IS FEASIBLE AND NOT BURDENSOME FOR PATIENTS WITH EOSINOPHILIC ESOPHAGITIS

Gastroenterology (New York, N.Y. 1943), 2020-05, Vol.158 (6), p.S-818-S-818

2020

Volltextzugriff (PDF)

Mo1182 AN EPISODE-BASED, PATIENT-REPORTED OUTCOME MEASURE OF DYSPHAGIA ACCURATELY CAPTURES RESPONSE TO TREATMENT WITH APT-1011 IN A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, CLINICAL TRIAL IN ADULTS WITH EOSINOPHILIC ESOPHAGITIS

Gastroenterology (New York, N.Y. 1943), 2020-05, Vol.158 (6), p.S-817-S-817

2020

Volltextzugriff (PDF)

S353 Time to Clinically Meaningful Improvement in Dysphagia Frequency in Adults with Eosinophilic Esophagitis: A Post-Hoc Analysis From a Phase 2b Trial of APT-1011, a Fluticasone Propionate Oral Disintegrating Tablet

The American journal of gastroenterology, 2021-10, Vol.116 (1), p.S152-S153

2021

Volltextzugriff (PDF)

S458 Patient-Reported Symptom Improvement Following Treatment With APT-1011 in Patients with Eosinophilic Esophagitis as Measured by the PROSE: Results from FLUTE, A Phase 2b Clinical Trial

The American journal of gastroenterology, 2021-10, Vol.116 (1), p.S203-S203

2021

Volltextzugriff (PDF)

EXTENSION STUDY OF AMIKACIN LIPOSOME INHALATION SUSPENSION (ALIS) FOR TREATMENT-REFRACTORY LUNG DISEASE CAUSED BY MYCOBACTERIUM AVIUM COMPLEX (MAC)

Chest, 2018-10, Vol.154 (4), p.182A-183A

2018

Volltextzugriff (PDF)

AN OPEN-LABEL EXTENSION STUDY OF AMIKACIN LIPOSOME INHALATION SUSPENSION (ALIS) FOR TREATMENT-REFRACTORY LUNG DISEASE CAUSED BY MYCOBACTERIUM AVIUM COMPLEX (MAC)

Chest, 2019-10, Vol.156 (4), p.A146-A147

2019

Volltextzugriff (PDF)

Effects of felbamate on the pharmacokinetics of phenobarbital

Clinical pharmacology and therapeutics, 1995-09, Vol.58 (3), p.279-287

1995

Volltextzugriff (PDF)

Cytoprotection by prostaglandins in rats: Prevention of gastric necrosis produced by alcohol, HCl, NaOH, hypertonic NaCl, and thermal injury

Gastroenterology (New York, N.Y. 1943), 1979-09, Vol.77 (3), p.433-443

1979

Volltextzugriff (PDF)

Effect of Alosetron on the Pharmacokinetics of Alprazolam

Journal of clinical pharmacology, 2001-04, Vol.41 (4), p.452-454

2001

Volltextzugriff (PDF)

Effect of Alosetron on the Pharmacokinetics of Fluoxetine

Journal of clinical pharmacology, 2001-04, Vol.41 (4), p.455-458

2001

Volltextzugriff (PDF)

Possible Relationship between Smoking and Peptic Ulcer

Nature (London), 1971-10, Vol.233 (5320), p.497-498

1971

Volltextzugriff (PDF)

Effect of Prostaglandin E1 on Gastric Secretion and Ulcer Formation in the Rat

Gastroenterology (New York, N.Y. 1943), 1968-10, Vol.55 (4), p.481-487

1968

Volltextzugriff (PDF)

Effect of an anti-acetylcholine drug, methscopolamine bromide, on ulcer formation and gastric mucus

Journal of pharmacy and pharmacology, 1964-10, Vol.16 (10), p.690-695

1964

Volltextzugriff (PDF)

The granuloma pouch as a routine assay for antiphlogistic compounds

Acta endocrinologica (Copenhagen), 1957-05, Vol.25 (1), p.105-112

1957

Volltextzugriff (PDF)

Inhibition by prostaglandin E1 of gastric secretion in the dog

The Journal of physiology, 1971-10, Vol.218 (2), p.369-383

1971

Volltextzugriff (PDF)

Different properties of two mucigogues, pilocarpine and mercuric acetate

The American journal of physiology, 1965-11, Vol.209 (5), p.877-886

1965

Volltextzugriff (PDF)

1 – 25 von 100

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(99)
Mit Volltextzugriff
(88)

Publikationsform

Artikel
(100)

Sprache

Englisch
(100)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Amikacin Liposome Inhalation Suspension for Treatment-Refractory Lung Disease Caused by Mycobacterium avium Complex (CONVERT). A Prospective, Open-Label, Randomized Study

Diffusing capacity and forced vital capacity in 5,003 asbestos-exposed workers: Relationships to interstitial fibrosis (ILO profusion score) and pleural thickening

Fluticasone Propionate Orally Disintegrating Tablet (APT-1011) for Eosinophilic Esophagitis: Randomized Controlled Trial

965 FLUTICASONE PROPIONATE ORAL DISINTEGRATING TABLET, APT-1011, LEADS TO A GREATER COMPLETE SYMPTOMATIC RESPONSE RATE COMPARED TO PLACEBO IN SUBJECTS WITH EOSINOPHILIC ESOPHAGITIS (EOE)

964 FLUTICASONE PROPRIONATE ORAL DISINTEGRATING TABLET, APT-1011, IMPROVES FIBROSTENOTIC FEATURES OF STRICTURES AND GRADE 2/3 RINGS IN SUBJECTS WITH EOSINOPHILIC ESOPHAGITIS (EOE)

S465 Development and Content Validity of the PROSE Daily Diary to Measure Dysphagia Episodes in Adults and Adolescents With Eosinophilic Esophagitis

540 FLUTICASONE PROPIONATE ORALLY DISINTEGRATING TABLET (APT-1011) IMPROVES HISTOLOGIC, ENDOSCOPIC AND SYMPTOMATIC RESPONSES IN EOSINOPHILIC ESOPHAGITIS PATIENTS WITH FIBRO-STENOTIC FEATURES: RESULTS FROM A PHASE 2B TRIAL

Fr172 LOW RATES OF GLUCOCORTICOID-RELATED ADVERSE EFFECTS WITH LONG-TERM TREATMENT OF EOSINOPHILIC ESOPHAGITIS WITH FLUTICASONE PROPIONATE ORALLY DISINTEGRATING TABLET (APT-1011): RESULTS FROM 52 WEEKS OF EXPOSURE IN A PHASE 2B TRIAL

S0345 Safety and Efficacy of Long-Term Treatment of EoE With Fluticasone Propionate Orally Disintegrating Tablet (APT-1011): Results From 40 Weeks Treatment in a Phase 2b Randomized Double-Blind Placebo-Controlled Trial

Mo1184 AN EPISODE-BASED PATIENT-REPORTED OUTCOME MEASURE OF DYSPHAGIA EXPERIENCE IS FEASIBLE AND NOT BURDENSOME FOR PATIENTS WITH EOSINOPHILIC ESOPHAGITIS

Mo1182 AN EPISODE-BASED, PATIENT-REPORTED OUTCOME MEASURE OF DYSPHAGIA ACCURATELY CAPTURES RESPONSE TO TREATMENT WITH APT-1011 IN A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, CLINICAL TRIAL IN ADULTS WITH EOSINOPHILIC ESOPHAGITIS

S353 Time to Clinically Meaningful Improvement in Dysphagia Frequency in Adults with Eosinophilic Esophagitis: A Post-Hoc Analysis From a Phase 2b Trial of APT-1011, a Fluticasone Propionate Oral Disintegrating Tablet

S458 Patient-Reported Symptom Improvement Following Treatment With APT-1011 in Patients with Eosinophilic Esophagitis as Measured by the PROSE: Results from FLUTE, A Phase 2b Clinical Trial

EXTENSION STUDY OF AMIKACIN LIPOSOME INHALATION SUSPENSION (ALIS) FOR TREATMENT-REFRACTORY LUNG DISEASE CAUSED BY MYCOBACTERIUM AVIUM COMPLEX (MAC)

AN OPEN-LABEL EXTENSION STUDY OF AMIKACIN LIPOSOME INHALATION SUSPENSION (ALIS) FOR TREATMENT-REFRACTORY LUNG DISEASE CAUSED BY MYCOBACTERIUM AVIUM COMPLEX (MAC)

Effects of felbamate on the pharmacokinetics of phenobarbital

Cytoprotection by prostaglandins in rats: Prevention of gastric necrosis produced by alcohol, HCl, NaOH, hypertonic NaCl, and thermal injury

Effect of Alosetron on the Pharmacokinetics of Alprazolam

Effect of Alosetron on the Pharmacokinetics of Fluoxetine

Possible Relationship between Smoking and Peptic Ulcer

Effect of Prostaglandin E1 on Gastric Secretion and Ulcer Formation in the Rat

Effect of an anti-acetylcholine drug, methscopolamine bromide, on ulcer formation and gastric mucus

The granuloma pouch as a routine assay for antiphlogistic compounds

Inhibition by prostaglandin E1 of gastric secretion in the dog

Different properties of two mucigogues, pilocarpine and mercuric acetate

Suchergebnisse filtern